Evidence map›Paper›PMID 34209302›Full record

ArticleCurrent oncology (Toronto, Ont.)2021

Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration.

Arslan Babar, Neil M Woody, Ahmed I Ghanem, Jillian Tsai, Neal E Dunlap, Matthew Schymick, Howard Y Liu, Brian B Burkey, Eric D Lamarre, Jamie A Ku and 11 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Surgery Versus Radiotherapy in Older Adults with Oral Cavity Cancer: A Nationwide Comparative Effectiveness Study.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 3 countries.

Arslan BabarDepartment of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Neil M WoodyDepartment of Radiation Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.
Ahmed I GhanemDepartment of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI 48202, USA.ORCID 0000-0002-3396-6763
Jillian TsaiDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Neal E DunlapDepartment of Radiation Oncology, University of Louisville Hospital, Louisville, KY 40202, USA.
Matthew SchymickDepartment of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI 48202, USA.
Howard Y LiuDepartment of Radiation Oncology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia.ORCID 0000-0002-9902-9529
Brian B BurkeyHead and Neck Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Eric D LamarreHead and Neck Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Jamie A KuHead and Neck Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Joseph ScharpfHead and Neck Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Brandon L PrendesHead and Neck Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Nikhil P JoshiDepartment of Radiation Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.
Jimmy J CaudellDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Farzan SiddiquiDepartment of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI 48202, USA.
Sandro V PorcedduDepartment of Radiation Oncology, University of Louisville Hospital, Louisville, KY 40202, USA.
Nancy LeeDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Larisa SchwartzmanDepartment of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.
Shlomo A KoyfmanDepartment of Radiation Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.
David J AdelsteinDepartment of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.
Jessica L GeigerDepartment of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.
Cleveland Clinic · USMemorial Sloan Kettering Cancer Center · USUniversity of Louisville Hospital · USAlexandria University · EGMoffitt Cancer Center · USPrincess Alexandra Hospital · AU

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, concurrent with radiation (RT), and the effect of cumulative dosing of cisplatin. An IRB-approved collaborative database of patients (pts) with primary OCSCC (Stage I-IVB AJCC 7th edition) treated with primary surgical resection between January 2005 and January 2015, with or without adjuvant therapy, was established from six academic institutions. Patients were categorized by cisplatin dose and schedule, and resultant groups compared for demographic data, pathologic features, and outcomes by statistical analysis to determine disease free survival (DFS) and freedom from metastatic disease (DM). From a total sample size of 1282 pts, 196 pts were identified with high-risk features who were treated with adjuvant CRT. Administration schedule of cisplatin was not significantly associated with DFS. On multivariate (MVA), DFS was significantly better in patients without perineural invasion (PNI) and in those receiving ≥200 mg/m

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsChemoradiotherapyHumansNeoplasm StagingSquamous Cell Carcinoma of Head and Neckchemoradiationcisplatincisplatin schedulecumulative cisplatin dosehigh risk oral cavity canceroral cavity squamous cell cancer

Identifiers

PMID34209302
PMCPMC8293216
OpenAlexW3173382128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.